We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+32.2%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$2.52B
AUM Growth
+$1.12B
(+80%)
Cap. Flow
+$772M
Cap. Flow
% of AUM
30.59%
Top 10 Holdings %
Top 10 Hldgs %
26.22%
Holding
205
New
69
Increased
52
Reduced
26
Closed
58
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intel
INTC
|
+$62.5M |
| 2 |
Johnson & Johnson
JNJ
|
+$61M |
| 3 |
Fidelity National Information Services
FIS
|
+$54.2M |
| 4 |
KLA
KLAC
|
+$44.1M |
| 5 |
PayPal
PYPL
|
+$41.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$65.7M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$46.8M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$46.5M |
| 4 |
IMMU
Immunomedics Inc
IMMU
|
+$41.2M |
| 5 |
Analog Devices
ADI
|
+$23.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.91% |
| 2 | Technology | 35.52% |
| 3 | Communication Services | 5.66% |
| 4 | Consumer Discretionary | 4.26% |
| 5 | Industrials | 2.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRTX
101
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $5.91M | 0.23% |
51,742
-49,211
| -49% | -$4.77M |
|
|
ONEM
102
DELISTED
1Life Healthcare
ONEM
| $5.89M | 0.23% |
+162,191
| New | +$4.57M |
|
103
Ambarella
AMBA
$3.77B
| $5.82M | 0.23% |
+127,117
| New | +$6.55M |
|
104
Immunovant
IMVT
$7.93B
| $5.62M | 0.22% |
230,908
-94,275
| -29% | -$2.02M |
|
|
DOYU
105
DouYu International Holdings
DOYU
$139M
| $5.53M | 0.22% |
+47,944
| New | +$4M |
|
106
Allogene Therapeutics
ALLO
$649M
| $5.51M | 0.22% |
+128,628
| New | +$4.65M |
|
107
DexCom
DXCM
$31.5B
| $5.31M | 0.21% |
52,384
-16,120
| -24% | -$1.44M |
|
108
Nutanix
NTNX
$16B
| $5.28M | 0.21% |
222,883
-235,232
| -51% | -$4.87M |
|
109
AMC Global Media
AMCX
$492M
| $5.28M | 0.21% |
+225,634
| New | +$5.91M |
|
110
Regenxbio
RGNX
$620M
| $5.22M | 0.21% |
141,711
-12,910
| -8% | -$481K |
|
|
PVLA
111
Palvella Therapeutics
PVLA
$1.99B
| $5.21M | 0.21% |
21,017
+7,954
| +61% | +$1.86M |
|
112
Silicon Laboratories
SLAB
$7.17B
| $5.11M | 0.2% |
+50,922
| New | +$4.76M |
|
|
TRIL
113
DELISTED
Trillium Therapeutics Inc.
TRIL
| $5.07M | 0.2% |
626,810
-27,971
| -4% | -$173K |
|
114
Dentsply Sirona
XRAY
$2.68B
| $4.93M | 0.2% |
+111,937
| New | +$4.73M |
|
|
PRVL
115
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
| $4.9M | 0.19% |
329,135
+77,603
| +31% | +$1.2M |
|
|
CTLT
116
DELISTED
CATALENT, INC.
CTLT
| $4.76M | 0.19% |
+64,880
| New | +$4.4M |
|
117
Agilent Technologies
A
$39.1B
| $4.72M | 0.19% |
53,454
-33,220
| -38% | -$2.72M |
|
|
BHVN
118
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $4.48M | 0.18% |
+61,221
| New | +$3.26M |
|
119
Avnet
AVT
$7.29B
| $4.47M | 0.18% |
+160,458
| New | +$4.45M |
|
120
Skyworks Solutions
SWKS
$9.37B
| $4.38M | 0.17% |
+34,255
| New | +$3.79M |
|
121
Abeona Therapeutics
ABEO
$366M
| $4.1M | 0.16% |
56,234
+7,901
| +16% | +$546K |
|
|
APTO
122
DELISTED
Aptose Biosciences, Inc.
APTO
| $3.79M | 0.15% |
1,334
+1,212
| +993% | +$3.91M |
|
123
Progyny
PGNY
$2.44B
| $3.62M | 0.14% |
+140,207
| New | +$3.22M |
|
|
RNAM
124
DELISTED
Avidity Biosciences
RNAM
| $3.53M | 0.14% |
+125,000
| New | +$3.6M |
|
|
VISN
125
Vistance Networks Inc
VISN
$2.65B
| $3.26M | 0.13% |
+391,345
| New | +$3.86M |
|
Similar funds
PAM
TCIIS
UIM
Woodline Partners's Q2 2020 Portfolio in Review
As of Q2 2020, Woodline Partners held 205 positions worth $2.52B, up 80% from $1.4B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Woodline Partners deployed $772M of net new capital in Q2 2020, opening 69 new positions and adding to 52 existing holdings. Its largest new stake was Johnson & Johnson: 418,880 shares worth $58.9M.
By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 46% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Immunomedics Inc, an estimated $41.2M trimmed.
- Woodline Partners's largest Q2 2020 buy was Johnson & Johnson: 418,880 shares worth $58.9M.
- Woodline Partners added most to Intel in Q2 2020, an estimated $62.5M increase.
- Woodline Partners's biggest Q2 2020 reduction was Immunomedics Inc, cutting an estimated $41.2M.
- Woodline Partners fully exited Pfizer in Q2 2020, selling an estimated $65.7M.
- Woodline Partners's ten largest holdings make up 26% of its $2.52B portfolio in Q2 2020.
- Woodline Partners opened 69 new positions and closed 58 in Q2 2020.
- Woodline Partners's portfolio value rose 80% quarter-over-quarter to $2.52B.
Based on Woodline Partners's 13F filing for Q2 2020, filed 14 Aug 2020.